Malaria Vaccine 257049 — Competitive Intelligence Brief

Malaria Vaccine 257049 (Malaria Vaccine 257049) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein vaccine. Area: Infectious Disease / Immunology.

phase 3 Recombinant protein vaccine Plasmodium falciparum circumsporozoite protein (CSP) and/or blood-stage antigens Infectious Disease / Immunology Biologic

Target snapshot

Malaria Vaccine 257049 (Malaria Vaccine 257049) — GlaxoSmithKline. This vaccine stimulates the immune system to recognize and attack Plasmodium parasites that cause malaria by targeting the parasite's pre-erythrocytic and blood-stage antigens.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Malaria Vaccine 257049 TARGET	Malaria Vaccine 257049	GlaxoSmithKline	phase 3	Recombinant protein vaccine	Plasmodium falciparum circumsporozoite protein (CSP) and/or blood-stage antigens
Licensed 4CMenB vaccine	Licensed 4CMenB vaccine	University of Adelaide	marketed	Recombinant protein vaccine	Neisseria meningitidis serogroup B surface antigens
Recombinant influenza hemagglutinin	Recombinant influenza hemagglutinin	Vaxine Pty Ltd	marketed	Recombinant protein vaccine	Influenza hemagglutinin
FluBlok	FluBlok	The University of Hong Kong	marketed	Recombinant protein vaccine	Influenza hemagglutinin (HA)
Licensed seasonal influenza vaccine	Licensed seasonal influenza vaccine	Novavax	marketed	Recombinant protein vaccine with adjuvant	Influenza hemagglutinin (HA) protein
Novavax recombinant protein vaccine	Novavax recombinant protein vaccine	Henry M. Jackson Foundation for the Advancement of Military Medicine	marketed	Recombinant protein vaccine	Viral surface antigens (e.g., SARS-CoV-2 spike protein)
Meningococcal B (Bexsero)	Meningococcal B (Bexsero)	University of Sao Paulo General Hospital	marketed	Recombinant protein vaccine	Meningococcal serogroup B surface antigens (recombinant Neisseria meningitidis proteins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein vaccine class)

1. GlaxoSmithKline · 6 drugs in this class
2. Novavax · 5 drugs in this class
3. Vaxine Pty Ltd · 2 drugs in this class
4. D'Or Institute for Research and Education · 2 drugs in this class
5. Protein Sciences Corporation · 2 drugs in this class
6. Henogen · 1 drug in this class
7. Henry M. Jackson Foundation for the Advancement of Military Medicine · 1 drug in this class
8. Institut National de la Santé Et de la Recherche Médicale, France · 1 drug in this class
9. National Vaccine and Serum Institute, China · 1 drug in this class
10. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 drug in this class